Kornimate/medical-research-clean huggingface dataset:
effect of cervical mobilization on balance and plantar pressure distribution in multiple sclerosis

Conditions: Multiple Sclerosis; Muscle Spasticity; Pressure Area; Cervical Region Disorder Nos

Summary: ms patients were randomly divided into traditional therapy and traditional therapy + cervical mobilization groups. while muscle strengthening, stretching, balance and coordination exercises were given to the traditional group, cervical mobilization was applied in addition to these in cervical group. patients received treatments twice a week for 4 weeks. the effect of the applied treatment on the tonus and plantar pressure distribution was analyzed. treatments were interrupted for 4 weeks and the groups continued with the treatment they did not receive (crossover design). the group that received traditional treatment in the first period completed traditional + cervical mobilization, and the other group with traditional + cervical mobilization traditionally completed the treatment.

cervical region is rich in terms of muscle spindle and reseptors. when this region is touched by physiotherapists, muscle spindles is activited. the cervical region is parasympathetic area have common relaxed effect. thus this part can be benefit to improvement of balance. as improve balance, the plantar pressure distribution of patients may change.

Eligibility criteria:
inclusion criteria: * expanded disability status scale (edss) score was between 2-5, * according to the modified ashworth scale, spasticity is between 1 and 3, * edss cerebellar system sub-scale, functional system score ˃1, * medical condition is stable and no medication changes were made in the last month, * vertebro-basillar test negative, * not have any other neurological disorder and orthopedic problem to prevent participation in this study * a score of at least 24 from the mini mental test, exclusion criteria: * presence of psychiatric or severe cognitive dysfunction, * pregnancy, * having a neurological disease other than ms, * having had an attack in the last 3 months, * botulinum toxin application within the last 6 months, * participating in physiotherapy program in the last 6 months

Keywords: cervical region multiple sclerosis muscle spasticity manual therapy cervical spine plantar pressure
embryo development in microfluidics system of culture

Conditions: Infertility

Summary: embryo culture is a cornerstone of in vitro fertilization treatments. usually, embryos are cultured in microdrops of culture media in incubators with controlled temperature, humidity and atmosphere. however, these culture systems are static, while in vivo the initial growth of the embryo takes place in the uterine tube and they are submitted to a dynamic environment. the aim of this study is to compare the embryo development on days 2 and 3 of culture morphological features of embryos under static and dynamic(microfluidics) systems of culture.

embryo culture is a cornerstone of in vitro fertilization treatments. usually, embryos are cultured in microdrops of culture media in incubators with controlled temperature, humidity and atmosphere. however, these culture systems are static, while in vivo the initial growth of the embryo takes place in the uterine tube and they are submitted to a dynamic environment. the aim of this study is to compare the embryo development on days 2 and 3 of culture morphological features of embryos under static and dynamic(microfluidics) systems of culture.

Eligibility criteria:
inclusion criteria: * age between 21 and 35 years old * no more than 1 previous ivf failure * absence of physical conditions that can interfere in oocyte quality * at least 8 zigotes 24 hours after fertilization exclusion criteria: * use of epididimary or testicular sperm * sperm or egg donation * untreated systemic diseases

Keywords: embryo culture ivf microfluidics infertility
attrax® putty vs. autograft in xlif®

Conditions: Degenerative Conditions of the Lumbar Spine

Summary: the objective of this study is to evaluate the clinical success of attrax putty as a bone graft substitute for autograft in xlif procedures.

this is a single-center, prospective, randomized study. subjects will be recruited from patients already under the investigator's care who are indicated for xlif with iliac crest bone graft (icbg) autograft or attrax putty. to minimize bias, all consecutive patients at a given investigational site who meet eligibility requirements will be asked to consent to participate in the study whereby the biologic (icbg autograft or attrax putty) will be randomly assigned. all subjects will be followed for 24 months following surgery to quantify the clinical and radiographic improvements of each biologic compared to baseline and in comparison with each other.

Eligibility criteria:
inclusion criteria: 1. persistent back and/or leg pain unresponsive to conservative treatment for at least 6 months, unless surgical treatment is clinically indicated sooner 2. indicated for a single-level xlif between l1 and l5 with bilateral percutaneous pedicle screws 3. objective evidence of primary diagnosis must be confirmed by appropriate imaging studies 4. 18-80 years of age at the date of written informed consent 5. able to undergo surgery based on physical exam, medical history, and surgeon judgment 6. expected to survive at least 2 years beyond surgery 7. willing and able to return for post-treatment exams according to the follow-up called for in the protocol 8. signed and dated informed consent form exclusion criteria: 1. mental or physical condition that would limit the ability to comply with study requirements 2. spine abnormality requiring treatment at more than one level 3. previous failed fusion at any spinal level 4. prior fusion procedure at operative level (i.e., no revision of operative level) 5. prior adjacent level fusion (note: prior decompression is not an exclusion) 6. systemic or local infection; active or latent 7. diseases that significantly inhibit bone healing (e.g., prior diagnosis of osteoporosis, metabolic bone disease) 8. treatment with pharmaceuticals interfering with calcium metabolism 9. undergoing chemotherapy or radiation treatment 10. chronic use of steroids (defined as more than 6 weeks of steroid use within 12 months of surgery, other than episodic use or inhaled corticosteroids) 11. involvement in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested) 12. significant general illness (e.g., hiv, active metastatic cancer of any type, uncontrolled diabetes, dialysis dependent renal failure, symptomatic liver disease) 13. immunocompromised or is being treated with immunosuppressive agents 14. pregnant, or plans to become pregnant during the study 15. subject is a prisoner 16. participating in another clinical study that would confound study data 17. at risk to be non-compliant (e.g. (recently treated for) substance abuse, detainee, likely to immigrate)

Keywords: degenerative disc disease lumbar spine
probiotic in patients with bile acid malabsorption/diarrhea

Conditions: Bile Acid Malabsorption; Bile Acid Diarrhea

Summary: the purpose of this study is to assess effect of the dsf probiotic on fecal bile acid levels in patients with bam.

in this placebo-controlled trial, the de simone combination probiotic formulation will be tested in 12 patients in each treatment arm. the patient's will be previously diagnosed with bile acid diarrhea. the objective is to assess the effects of this probiotic on fecal blood low acid levels in patients with bile acid diarrhea. secondary objectives are to evaluate changes in% primary fecal bile acids in a single stool sample, serum 7 alpha c4, intestinal permeability, stool consistency and frequency, fecal short chain fatty acids, and fecal micro biome composition and diversity

Eligibility criteria:
inclusion criteria: * prior diagnosis of bile acid malabsorption documented in the medical history based on * either serum c4 \>52.5ng/ml, or * fecal 48h total ba excretion \>2337 μmol/48h, or * primary ba \>5% 48h stool collection or \>10% in single stool sample. * 7-day stool dairy with an average stool consistency based on the bristol stool form scale, bsfs, with a grade greater than 5. note: if inclusion criteria 3 is not met, participants may choose to have their blood drawn clinically to further determine eligibility. * for women of childbearing potential * a negative urine pregnancy test prior to dispensing the study product * agreement to comply with approved methods of contraception during the whole study: unless they meet the criteria of post-menopausal, i.e. 12 months of spontaneous amenorrhea, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner, should use one or more of the following acceptable methods of contraception that should be maintained throughout the study: * surgical sterilization * hormonal contraception (implantable, patch, oral, intra-muscular) * intra-uterine device * double barrier method (diaphragm plus condom) * at the discretion of the investigator, total abstinence is acceptable in cases where age, career, lifestyle, or sexual orientation of the patient ensures compliance exclusion criteria: * use of oral antibiotics and probiotics within the last 4 weeks. * pregnancy or lactation. * concomitant use of bile acid sequestrants, must stop 10 days before starting 7-day stool dairy and for the duration of the study. * history of ileal resection. * diabetes mellitus (type 1) * bmi ≥ 40 kg/m\^2 * diagnosis of gastrointestinal diseases that are associated with inflammation such as inflammatory bowel diseases and celiac diseases or gastrointestinal infection in the prior 4 weeks * any condition or personal circumstance that, in the opinion of the investigator, renders the subject unlikely or unable to comply with the full study protocol or could interfere with the study assessments
effectiveness of endoscopic papillectomy with stent for treating duodenal papillary adenoma

Conditions: Duodenal Adenoma; Complication of Treatment

Summary: this is a retrospective study, including 79 patients with duodenal papillary adenoma, who treated with endoscopic papillectomy (ep) at beijing friendship hospital. the cohort included patients who underwent ep with or without pancreatic duct (pd) and common bile duct (cbd) stent placement. the investigators assessed the outcomes of ep and the impact of stent placement on complications and recurrence rates.

duodenal papillary adenoma, a potentially malignant benign tumor is primarily treated with endoscopic papillectomy. despite its efficacy, endoscopic papillectomy has a high complication rate. this study investigates whether pancreatic duct and common bile duct stent placement can mitigate these complications. in a retrospective analysis, 79 patients with duodenal papillary adenoma, treated with endoscopic papillectomy at our center, were studied. the cohort included patients who underwent endoscopic papillectomy with no stents placement, common bile duct stent placement alone, pancreatic duct stent placement alone, or stents placement in both ducts. complete resection rates did not significantly differ between patients with or without stent placement. early complication rates were similar across groups. however, significant reduction in common bile duct stenosis was observed in the stenting group. furthermore, stent placement correlated with lower adenoma recurrence rates during follow-up. thus, pancreatic duct and common bile duct stent placement in endoscopic papillectomy may decrease late complications, particularly common bile duct stenosis, and reduce the recurrence of duodenal papillary adenoma.

Eligibility criteria:
inclusion criteria: * age ≥18 years. * identification of duodenal papillary lesions via gastroscopy or duodenoscopy. * intraductal involvement \<20mm. * absence of preoperative peripheral lymph node metastasis and pancreatic/biliary duct stenosis (verified by ct, mri, or other imaging). * postoperative biopsy confirming adenoma. exclusion criteria: * diagnosis of familial adenomatous polyposis or multiple hamartoma syndrome. * patients undergoing pancreaticoduodenectomy within a month post-ep for residual lesions.

Keywords: duodenal papillary adenoma endoscopic duodenal papillectomy pancreatic duct stent common bile duct stent complication
innovative osa screening in head and neck cancer patients with the apneal app

Conditions: Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS); Head and Neck Cancers

Summary: obstructive sleep apnea syndrome is a common but often underdiagnosed condition, with significant impacts on quality of life, such as fatigue, attention disorders, and an increased risk of heart attack or stroke. structural changes in the head and neck region appear to contribute to the onset or worsening of this condition. to improve patients' quality of life, early diagnosis is essential. currently, diagnosis relies on expensive devices, often associated with long waiting times. to address these challenges, an innovative solution is proposed: a smartphone application enabling a simple and accessible diagnosis. this application is currently under validation and has not yet been commercialized. the purpose of the study is to determine whether this smartphone application can be used in clinical practice for patients with a head and neck lesion to diagnose sleep apnea syndrome and to assess its progression during the medical care. this study is for patients who present a head and neck lesion currently under evaluation in our department at caen university hospital. this research will be integrated into routine follow-up for a period of six months. the medical device used in this study, apneal, is a smartphone application currently undergoing validation for the rapid diagnosis of sleep apnea syndrome. its use is simple: the smartphone is placed in airplane mode and secured to the chest overnight. using the phone's built-in sensors, respiratory sleep data is collected and analyzed. as part of the initial assessment, a dedicated sleep consultation is included, during which a few questionnaires are completed, followed by an overnight sleep recording using the apneal application. this will be conducted at the beginning of the care during the assessment phase and again six months after the completion of any potential treatment. depending on the results, if they are inconclusive, an additional sleep recording may be required using a ventilatory polygraphy device. this study involves only two overnight recordings with a smartphone secured to the chest, which we will set up during the consultation.


Eligibility criteria:
inclusion criteria: * adult patients undergoing diagnostic workup for a lesion suspected to be a head and neck cancer, followed by confirmation of the malignant nature of the lesion. the following locations will be included: the nasopharynx, nasal cavities, sinuses, oral cavity, oropharynx, hypopharynx, larynx, and parotid gland. * the collection of the informed consent signature is required. * the patient must be affiliated with the social security system. exclusion criteria: * minor patients, or those under judicial protection, guardianship, or curators. * lack of confirmation of the malignant nature of the lesion. * diagnosis of metastatic cancer. * known history of obstructive sleep apnea syndrome (osas) or previously treated head and neck cancer.
immune response to seasonal influenza vaccination in multiple sclerosis patients receiving cladribine

Conditions: Multiple Sclerosis, Relapsing-Remitting; Vaccine Response Impaired

Summary: the primary objective of this study is to characterize the antibody response to seasonal influenza vaccine, in patients with active rrms, treated with cladribine, compared to control individuals with basic immunomodulatory treatment. serum antibody titers against the respective pathogen will be assessed prior to and 6 to 8 months following vaccination.


Eligibility criteria:
inclusion criteria: 1. signed informed consent form (icf) 2. age 18 to 60 years old (inclusive) as of the date the icf is signed 3. diagnosis of rrms according to the revised mcdonald criteria 4. edss score of 0.0 to 7.0 (inclusive) 5. in case of participants who are subjected to influenza vaccination by the treating physicians prior to cladribine the first or second cycle of cladribine (cohort 1 + cohort 3), this should be performed at least 4 to 6 weeks before the start of cladribine. definition of control group: patients with active rrms treated with cladribine will be compared to sex and age matched control individuals, with rrms under basic treatment either with interferon beta, glatiramer acetate, dimethyl fumarate or teriflunomide, who provide sample material prior to and 6 to 8 months after routine seasonal influenza vaccination during the same period. exclusion criteria: 1. previous treatment with b-cell targeted therapies (e.g., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab) 2. any previous treatment with alemtuzumab, cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation 3. medical, psychiatric, cognitive, or other conditions that, in the investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, or to complete the study 4. patients that receive immunosuppressive treatment for diseases other than ms or that receive long-term corticosteroid treatment 5. patients that received apheresis procedures 6 weeks prior to vaccination or in-between vaccination and dmt initiation 6. systemic high dose corticosteroid therapy within 6 weeks prior to vaccination or in-between vaccination and dmt initiation 7. patients with verified infection by human-immunodeficiency-virus or hepatitis-c-virus 8. patients with major impairment of the blood coagulation system including therapy with anticoagulants 9. patients with known chicken egg allergy

Keywords: influenza vaccination cladribine
safety and tolerability of long-term administration of hydromorphone hci cr (controlled release)

Conditions: Pain; Analgesics, Opioid

Summary: the purpose of study was to characterize the safety and tolerability of long-term repeated dosing of oros hydromorphone controlled release tablets (8,16,32, and 64 mg) in patients with chronic cancer pain or chronic non-malignant pain.

this was a phase 3, multicenter, open-label, extension study to characterize the safety and tolerability of long-term, repeated dosing of oros hydromorphone in patients with chronic cancer or chronic non-malignant pain. patients with chronic cancer or chronic non-malignant pain had completed an oros hydromorphone short-term study (do-104, do-105, do-119) of approximately 4 weeks duration. during this study, patients continued to receive the dose of oros hydromorphone that they had been receiving in the short-term study, with dose adjustments as needed to control pain and adverse events. patients were treated on an outpatient basis. the study was extended from 1 year to up to 2 years in duration. monthly evaluations of patients treated with oros hydromorphone for chronic pain were performed to identify adverse events, construct a safety and tolerability profile, and assess efficacy. dose adjustments were permitted to provide for disease progression, pain control, and adverse events. quarterly physical examinations were performed to detect significant changes in the underlying condition of patients or changes that may have been associated with long-term opioid therapy. oros hydromorphone 24 hour controlled release tablets in 8, 16, 32 and 64 mg were ingested orally daily up to 1 year with dose adjustments as needed to control pain and adverse events.

Eligibility criteria:
inclusion criteria: * patients who have chronic cancer or chronic non-malignant pain, including pain associated with aids, who have successfully completed a oros hydromorphone hci (controlled release) short-term study (i.e. study do-104, do-105, or do-119) * patients who require at least 8 mg of hydromorphone hci every 24 hours for the management of chronic cancer or chronic non-malignant pain * patients whose opioid requirements have been stable as demonstrated in a oros hydromorphone hci (controlled release) short-term study exclusion criteria: * patients intolerant of or hypersensitive to hydromorphone (or other opioid agonists) * patients who are pregnant or breast-feeding * patients with any gastrointestinal disorder, including pre-existing severe gi narrowing (pathologic or iatrogenic) that may affect the absorption or transit of orally administered drugs * patients with clinically significant impaired renal or hepatic function, addison's disease, hypothyroidism, prostatic hypertrophy, or urethral stricture * patients with any significant cns disorder, including but not limited to head injury, intracranial lesion, increased intracranial pressure, seizure disorder, stroke within the past 6 months, and disorders of cognition * patients who are known active drug abusers or alcoholics

Keywords: chronic cancer pain chronic pain
evaluation of recombinant factor viia in patients with severe bleeding

Conditions: Acquired Bleeding Disorder; Trauma

Summary: this trial is conducted globally. the purpose of the trial is to evaluate that activated recombinant human factor vii (eptacog alfa (activated)) is safe and effective in severely injured trauma patients by assessing mortality and morbidity. please note that this trial and trial f7trauma-1648 (nct00323570) have been merged.

the decision to discontinue the f7trauma-1711 trial is not due to any safety concerns. the result of the pre-planned futility analysis performed in june 2008 predicted a very low likelihood of reaching a successful outcome on the primary efficacy endpoint at the end of the trial and as a consequence, the company has decided to close the trial as this juncture.

Eligibility criteria:
inclusion criteria: * trauma injury (blunt and/or penetrating) with evidence of active hemorrhage (torso and/or proximal lower extremity) refractory to blood component therapy and surgical haemostatic procedures at the time of randomisation
comparison of saccharomyces boulardii and nystatin prophylaxis on candida colonization and infection in very low birth weight infants

Conditions: Anticandidal Property of Saccharomyces Boulardii on Very Low Birth Weight Infants

Summary: probiotics are favorable microorganisms that regulate the flora of the gastrointestinal system and stimulate the immune system. saccharomyces boulardii was shown to reduce candida colonization. the objective of this study is to evaluate the efficacy of prophylactic s boulardii in reducing the candida colonization and infection in very low birth weight infants.


Eligibility criteria:
inclusion criteria: * very low birth weight infants \< 1500 gr exclusion criteria: * genetic anomalies * not willing to participate * allergy to s. boulardii components